摘要
目的:探讨帕利哌酮与喹硫平治疗新型毒品所致的精神病性障碍患者的临床疗效及安全性。方法:将新型毒品所致的精神病性障碍患者80例,随机分为观察组(n=40例)与对照组(n=40例)。观察组给予帕利哌酮缓释片治疗,对照组给予喹硫平片治疗。以阳性和阴性症状评定量表(PANSS)和治疗不良反应量表(TESS)评价两组患者的临床疗效与不良反应发生情况。结果:两组患者在治疗后4周,帕利哌酮组总有效率为97.50%,喹硫平组总有效率为95.00%,两者间的疗效差异无显著性(P>0.05)。两组PANSS总分及各因子分均较治疗前显著下降(P<0.05),帕利哌酮组在第1、2周末的PANSS评分明显低于喹硫平组(P<0.05),其余时点两组比较无差异性(P>0.05)。两组药物均无严重不良反应,不良反应总体发生率两组间差异无显著性(P>0.05),帕利哌酮组患者的锥体外系副反应明显高于喹硫平组,肝功能损害、嗜睡等不良反应明显低于喹硫平组。结论:帕利哌酮缓释片与喹硫平片在治疗新型毒品所致精神障碍均有效,总体疗效相当,帕利哌酮起效更快。不良反应发生率相当但特点不同。
Objective： To investigate the treatment efficacy and safety of paliperidone and quetiapine in the treatment of new-type drug-induced mental disorder. Methods： 80 patients diagnosed with the new-type drug-induced mental disorder were randomly assigned to the research group （n=40） and the control group （n=40）. The research group was treated with paliperidone extended release, while the control group was treated with quetiapine. Results： No significant difference （p〉0.05） was found between two groups after 4-week treatment, as the paliperidone group showed the total response rate of 97.50% and the quetiapine group that of 95.00%. The scores of PANSS dropped significantly （p〈0.05） after treatment in both groups. The scores of PANSS for the paliperidone group were significantly lower than those for the quetiapine group after 1-week and 2-week treatment （p〈0.05）, and no significant difference （p〉0.05） was found at other times for the two groups. No severe side effects were found in both groups. The rate of adverse reaction showed significant difference （p〉0.05） between two groups. The paliperidone group had higher incidence of extrapyramidal side effects and lower incidence of liver function impairment, hypersomnia etc. than the quetiapine group. Conclusion： Paliperidone extended release and quetiapine had equivalent overall efficacy in the treatment of new-type drug-induced mental disorder, while paliperidone took action faster. The two drugs had different side-effect profile, but the incidence rates of side effects were equivalent for them.
作者
田文忠
田文聪
TIAN Wen-zhong, TIAN Wen-cong(Chongqing Psychiatric Hospital, Chongqing, 40003)
出处
《中国药物滥用防治杂志》
CAS
2018年第2期77-80,共4页
Chinese Journal of Drug Abuse Prevention and Treatment
